Taysha Gene Therapies is expected to report a Q3 2026 loss of $0.14 per share on revenue of $0.76 million, while the stock currently trades at $4.14 against a consensus price target of $12.77. The primary focus for investors is the clinical progress of TSHA-102 in Rett syndrome, specifically safety and efficacy data from the pediatric and adolescent cohorts of the REVEAL trial.
Management has indicated that its BLA-enabling manufacturing campaign remains on track for completion in Q4 2026, a pivotal milestone for regulatory filing. Despite widening year-over-year losses due to increased trial activity, a robust cash position of approximately $455 million is expected to fund operations into the second half of 2028.